Skip to main content
Does B Cell Depletion Matter?

Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna,

Dr. John Cush RheumNow

2 years 2 months ago
Does B Cell Depletion Matter? Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna, Austria. https://t.co/SX7BkX3w1T https://t.co/H1rD0n8GnK
Ultraprocessed Foods Increase Lupus Risk

In a study spanning over 25 years, women who consumed high amounts of "ultrap

Dr. John Cush RheumNow

2 years 2 months ago
Ultraprocessed Foods Increase Lupus Risk In a study spanning over 25 years, women who consumed high amounts of "ultraprocessed" foods had a 50% higher risk of developing SLE compared to those with low consumption. https://t.co/7ICeAFRjRG https://t.co/Vi1lBe7neQ
174 Active RA pts not responding to MTX were started on TCZ. High GM-CSF (> 5 ng/ml and > 10 ng/ml) at basel

Dr. John Cush RheumNow

2 years 2 months ago
174 Active RA pts not responding to MTX were started on TCZ. High GM-CSF (> 5 ng/ml and > 10 ng/ml) at baseline were the independent predictors of poor response to TCZ at Wk24. high GM-CSF had signif higher DAS28-ESR & cytokine levels at baseline https://t.co/vy7czYwv1Z https://t.co/R2cYdNZ3V0
Pollution and Autoimmunity (7.12.2024)

Dr. Jack Cush reviews the news and journal articles from the past week on https

Dr. John Cush RheumNow

2 years 2 months ago
Pollution and Autoimmunity (7.12.2024) Dr. Jack Cush reviews the news and journal articles from the past week on https://t.co/V10S4oVFsv. https://t.co/c4Eo4EpOj8
Intercurrent infections may be assoc w/ SLE flares. 203 Amsterdam SLE pts, incidence of major & minor infections wer

Dr. John Cush RheumNow

2 years 2 months ago
Intercurrent infections may be assoc w/ SLE flares. 203 Amsterdam SLE pts, incidence of major & minor infections were 5.3 & 64/100Pys. Intercurrent infections (major & minor) were assoc w/ SLE flares (HR 1.9); major infx lead to major SLE flares (HR 7.4) https://t.co/DSPgi9KrwT https://t.co/FI7ZYf3CPl
Later onset PsO may benefit from earlier PsA screening. Cohort study of 384 Psoriasis pts. Older PsO onset assoc w/ sho

Dr. John Cush RheumNow

2 years 2 months ago
Later onset PsO may benefit from earlier PsA screening. Cohort study of 384 Psoriasis pts. Older PsO onset assoc w/ shorter interval from PsO to PsA. PsO onset at 42.6 yrs had a 62% shorter interval & OR 4.56 to have PsA w/in 6 mos. https://t.co/DSiYs88MFa https://t.co/reID2wvLiu
Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc.
268/279 SLE pts w/ kidney biopsy for proteinuria were Dx w/ lupus nephritis. Proliferative LN (III/IV+V) had higher leve

Dr. John Cush RheumNow

2 years 2 months ago
268/279 SLE pts w/ kidney biopsy for proteinuria were Dx w/ lupus nephritis. Proliferative LN (III/IV+V) had higher levels of C1q, chromatin, dsDNA, ribosomal P Abs. C1q & dsDNA independently assoc w/ proliferative LN. AutoAbs decreased in proliferative LN https://t.co/tRucgJRpDN https://t.co/DtgEmGhUzd
Pathogenesis of Autoimmune Liver Disease
  • EurekAlert!
Autoimmune liver diseases (ALDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage. These diseases are increasingly prevalent, but their pathogenesis remains largely unclear.
AbbVie has submitted regulatory applications to both the FDA and the European Medicines Agency for Rinvoq (upadacitinib)

Dr. John Cush RheumNow

2 years 2 months ago
AbbVie has submitted regulatory applications to both the FDA and the European Medicines Agency for Rinvoq (upadacitinib) to treat adult patients with giant cell arteritis (GCA) https://t.co/LqRcm2FEFV https://t.co/XEjjSNnOGt
Full read overview of myositis associated - ILD (and treatments), including:
- Case examples
- Antisynthetase Syndrome

Dr. John Cush RheumNow

2 years 2 months ago
Full read overview of myositis associated - ILD (and treatments), including: - Case examples - Antisynthetase Syndrome - Anti-MDA5 Amyopathic DM - Interstitial Lung Disease in Myositis https://t.co/zQpfstnGy8 https://t.co/XogyyxuVMk
Preliminary results from RESET-RA Study announced; demonstrating ACR20 efficacy of implanted vagal nerve stimulation at

Dr. John Cush RheumNow

2 years 3 months ago
Preliminary results from RESET-RA Study announced; demonstrating ACR20 efficacy of implanted vagal nerve stimulation at 12 wks (p=0.0209). 2-staged, multicenter, randomized, sham-controlled, double-blind pivotal trial, enrolled 242 RA pts https://t.co/gIVJd9F6Pk https://t.co/SNjWIa3raB
Study from the UK Biobank (n 459K) shows long-term exposure to air pollutants (PM2.5, PM10, NO2, and NOx) may increase t

Dr. John Cush RheumNow

2 years 3 months ago
Study from the UK Biobank (n 459K) shows long-term exposure to air pollutants (PM2.5, PM10, NO2, and NOx) may increase the risk of #SLE. 399 SLE pts (F/U 11.8 yrs) found an 18027% incr SLE risk w/ pollutants; magnified in those with high genetic risk https://t.co/PI4rvKwfpj https://t.co/2CZ28rHVG2
Efficacy of Biologics in Patients with CKD

A retrospective cohort study of biological bDMARDs persistence in RA patient

Dr. John Cush RheumNow

2 years 3 months ago
Efficacy of Biologics in Patients with CKD A retrospective cohort study of biological bDMARDs persistence in RA patients w/CKD, shows the 3 year survival to be > 50% but all studied biologics were nearly equivalents with regard to safety and efficacy. https://t.co/rL2ZondUsE https://t.co/1hM237Jl83
In the US CorEvitas registry of 1823 PsA pts; 11.1% fulfilled fibromyalgia definition & 20.6% had widespread pain. F

Dr. John Cush RheumNow

2 years 3 months ago
In the US CorEvitas registry of 1823 PsA pts; 11.1% fulfilled fibromyalgia definition & 20.6% had widespread pain. FM was assoc w/ female, depression/anxiety, impaired function, increased BMI, comorbidities. cDAPSA, patient pain& TJC https://t.co/YwRBYo1aR6 https://t.co/TXraU0F3Mh
×